Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus CLORAZEPATE DIPOTASSIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus CLORAZEPATE DIPOTASSIUM.
CENTRAX vs CLORAZEPATE DIPOTASSIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Binds to benzodiazepine site on gamma-aminobutyric acid type A (GABAA) receptors, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and decreased excitability.
10-30 mg orally, 3-4 times daily.
15-60 mg/day orally in divided doses 2-4 times daily; usual starting dose 15 mg at bedtime or 15 mg twice daily.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
40-50 hours (clorazepate is a prodrug rapidly converted to nordiazepam); effective half-life of nordiazepam is 40-100 hours. Accumulation occurs with repeated dosing, leading to prolonged sedation in elderly or hepatic impairment.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Primarily renal (60-70% as oxazepam glucuronide and other metabolites), with 15-20% biliary/fecal elimination. Less than 1% excreted unchanged.
Category C
Category D/X
Benzodiazepine
Benzodiazepine